drugset / Trial / NCT05494762
Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors
Non-randomizedSequentialOpen-labelTreatment
Summary
This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid tumors.
Timeline
- Start
- 2022-08-25
- Primary completion
- 2025-02-24
- Completion
- 2025-02-24
Outcome
Outcome not reported
Stopped (Business): “Sponsor decision”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BGB-B167 | Unknown | — | Intravenous |
| Subject | Tislelizumab | Monoclonal antibody | — | Intravenous |